- Home
- GHRS vs EVT Comparison
GHRS vs EVT Comparison
Compare GHRS & EVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GHRS | EVT |
|---|---|---|
| Founded | 2018 | N/A |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2021 | 2003 |
Fundamental Metrics
Financial Performance| Metric | GHRS | EVT |
|---|---|---|
| Price | $18.52 | $26.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $42.89 | N/A |
| AVG Volume (30 Days) | ★ 323.8K | 89.1K |
| Earning Date | 11-17-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.04 | $23.00 |
| 52 Week High | $31.44 | $29.65 |
Technical Indicators
Market Signals| Indicator | GHRS | EVT |
|---|---|---|
| Relative Strength Index (RSI) | 36.52 | 36.68 |
| Support Level | $17.54 | $25.97 |
| Resistance Level | $22.51 | $26.72 |
| Average True Range (ATR) | 1.27 | 0.44 |
| MACD | 0.19 | -0.04 |
| Stochastic Oscillator | 21.68 | 10.71 |
Price Performance
Historical ComparisonAbout GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.